Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118957 · ClinicalTrials.gov registry record · Phase 2
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
A Phase 2 study of Thromboembolism, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06118957: Completed Phase 2 study of Thromboembolism, sponsored by University of Utah.
NCT06118957 is a Phase 2 study of Thromboembolism that has completed, run by University of Utah. The registered enrollment target is 64 participants, below the 307-participant average among 8 other Thromboembolism trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06118957, a Phase 2 study of Thromboembolism, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.
Primary Outcome
Feasibility as defined by ≥35% enrollment of eligible individuals and retention ≥85% of enrolled individuals through all study procedures
Conditions Studied
Interventions
- DRUG Enoxaparin
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 2 |
What the finished NCT06118957 record still lists
NCT06118957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 307-participant average among 8 other Thromboembolism trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Enoxaparin is the first listed.
NCT06118957 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06118957 about?
NCT06118957 is a clinical study titled "Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery". The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the a...
What is the current status of trial NCT06118957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-10-11. Estimated completion is 2024-07-01.
What conditions does trial NCT06118957 study?
This clinical trial studies the following conditions: Thromboembolism.
What interventions are being tested in trial NCT06118957?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT06118957?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118957 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06118957's enrollment target sits among peer trials
64 6th of 8 higher than 3 of 8 other Thromboembolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
COMPLETED · Phase 2
-
In Vivo Detection of Circulating Clots in Patients With Thromboembolism
RECRUITING · NA
-
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
ACTIVE NOT RECRUITING · Phase 4
-
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
COMPLETED
-
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI